Company Recognition and Certifications - The company was awarded the "Jiangxi Famous Brand Product" for its Vitamin C Chewable Tablets in June 2023[3]. - The company’s subsidiary, Jiangxi Zhongyuan Pharmaceutical Co., Ltd., received the "High-tech Enterprise Certificate" from multiple government bodies in November 2023[3]. - The company has been recognized as a "High-tech Enterprise" and has achieved provincial-level recognition for its specialized and innovative capabilities[44]. Financial Performance - The company's total revenue for 2023 was approximately ¥216.48 million, representing a year-over-year increase of 2.53% compared to ¥211.15 million in 2022[25]. - The net profit attributable to shareholders decreased by 1.63% to ¥45.57 million in 2023 from ¥46.32 million in 2022[25]. - The gross profit margin improved to 47.15% in 2023, up from 46.07% in 2022[25]. - Total assets increased by 47.49% to ¥521.93 million at the end of 2023, compared to ¥353.88 million at the end of 2022[27]. - The company's total liabilities decreased by 32.28% to ¥48.21 million in 2023 from ¥71.19 million in 2022[27]. - The net asset attributable to shareholders rose by 68.97% to ¥470.58 million in 2023, compared to ¥278.50 million in 2022[27]. - The basic earnings per share fell by 24.44% to ¥0.68 in 2023 from ¥0.90 in 2022[25]. - The cash flow from operating activities was ¥40.43 million in 2023, down from ¥89.42 million in 2022[27]. - The company reported a non-recurring profit and loss of approximately ¥9.41 million in 2023, compared to ¥1.15 million in 2022[33]. Shareholder and Stock Information - The total share capital of the company is 70,861,250 shares[17]. - The company issued 19,636,250 shares in a public offering on February 9, 2023, with 3,415,000 shares subject to a 6-month lock-up period[138]. - As of December 31, 2023, the controlling shareholder, Zhang Aijiang, holds 49.19% of the company's shares directly and an additional 7.01% indirectly through Kaida Consulting, totaling 56.20%[145]. - The actual controllers, including Zhang Aijiang, Zhang Ming, Zhang Jia, Zhang Mi, and Yan Qipeng, collectively hold 70.86% of the company's shares[146]. - The total number of ordinary shareholders is 3,896[137]. Regulatory Compliance and Industry Standards - The company operates under strict industry regulations, including drug production licenses and quality management systems, as mandated by the 2019 revised Drug Administration Law[54]. - The company adheres to the national drug standards set by the State Drug Administration, ensuring compliance with the Pharmacopoeia of the People's Republic of China[55]. - The company is required to conduct consistency evaluations for generic drugs to ensure they match the quality and efficacy of original drugs, as per national guidelines[59]. - The company is subject to a series of legal regulations, including the Drug Administration Law and various management measures, to ensure drug safety and quality[60]. Research and Development - R&D expenditure amounted to ¥10,028,631.66, representing 4.63% of operating income, an increase from 4.20% in the previous period[100][99]. - The number of patents owned by the company increased to 67 from 53, with the number of invention patents rising to 9 from 8[102]. - The company has completed clinical trials for the new drug Succinic Acid Doxylamine, aiming to enhance product quality and market competitiveness[104]. - The company is conducting research to improve the quality of Gluconate Calcium and Gluconate Zinc, which will enhance product quality and profitability[104]. - The company is actively expanding its product portfolio through new drug development and technological advancements[199]. Market Strategy and Sales - The company employs a mixed sales strategy of distribution and direct sales for its chemical drug formulations and traditional Chinese medicine products[41]. - The sales model for chemical raw materials primarily involves direct sales to downstream formulation manufacturers, establishing long-term partnerships with key clients[40]. - The company aims to strengthen its sales team and optimize its sales system to promote sustainable growth in its main business[117]. - The company has established long-term partnerships with major clients in the industry, ensuring stable sales channels for its raw materials[195]. Environmental and Quality Management - The company is committed to adhering to strict quality, environmental, and health standards as part of its operational strategy[179]. - The company has established an environmental protection and safety production team to ensure compliance with national regulations[120]. - The company is actively exploring energy-saving and emission-reduction technologies in its production processes[120]. Future Outlook and Growth Plans - The company plans to continue optimizing its product sales structure and enhancing brand influence to support future growth[46]. - The company aims to enhance its internationalization level and modernize its industrial chain by 2035, as outlined in the national pharmaceutical development plan[71]. - The company plans to increase R&D investment and market promotion to enhance brand recognition and establish a comprehensive health ecosystem in 2024[116]. - The company has set a future outlook with a revenue target of 1.5 billion CNY for the next fiscal year, indicating a projected growth of 25%[185].
新赣江(873167) - 2023 Q4 - 年度财报